Parametric Portfolio Associates LLC Purchases 20,042 Shares of Arvinas Inc (NASDAQ:ARVN)

Parametric Portfolio Associates LLC boosted its position in shares of Arvinas Inc (NASDAQ:ARVN) by 115.9% in the 1st quarter, HoldingsChannel.com reports. The firm owned 37,339 shares of the company’s stock after buying an additional 20,042 shares during the quarter. Parametric Portfolio Associates LLC’s holdings in Arvinas were worth $1,505,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in ARVN. Swiss National Bank increased its stake in shares of Arvinas by 3.3% in the 1st quarter. Swiss National Bank now owns 37,800 shares of the company’s stock valued at $1,523,000 after acquiring an additional 1,200 shares during the last quarter. Credit Suisse AG increased its stake in shares of Arvinas by 105.6% in the 4th quarter. Credit Suisse AG now owns 26,601 shares of the company’s stock valued at $1,093,000 after acquiring an additional 13,663 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Arvinas by 8.8% in the 1st quarter. Rhumbline Advisers now owns 27,501 shares of the company’s stock valued at $1,108,000 after acquiring an additional 2,214 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in shares of Arvinas by 905.5% in the 1st quarter. BNP Paribas Arbitrage SA now owns 24,966 shares of the company’s stock valued at $1,006,000 after acquiring an additional 22,483 shares during the last quarter. Finally, Nuveen Asset Management LLC increased its stake in shares of Arvinas by 20.3% in the 4th quarter. Nuveen Asset Management LLC now owns 217,212 shares of the company’s stock valued at $8,926,000 after acquiring an additional 36,587 shares during the last quarter. 82.42% of the stock is owned by hedge funds and other institutional investors.

In other news, CFO Sean A. Cassidy sold 10,000 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $60.00, for a total value of $600,000.00. Following the completion of the sale, the chief financial officer now owns 150,422 shares of the company’s stock, valued at approximately $9,025,320. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Timothy M. Shannon acquired 3,000 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The stock was bought at an average cost of $32.88 per share, with a total value of $98,640.00. The disclosure for this purchase can be found here. Corporate insiders own 10.99% of the company’s stock.

NASDAQ:ARVN opened at $33.54 on Wednesday. The company has a market cap of $1.25 billion, a P/E ratio of -15.18 and a beta of 1.87. The company has a quick ratio of 8.15, a current ratio of 8.15 and a debt-to-equity ratio of 0.02. Arvinas Inc has a twelve month low of $15.19 and a twelve month high of $61.57. The business has a 50 day moving average price of $37.58 and a two-hundred day moving average price of $44.34.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings data on Tuesday, April 28th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.01. The company had revenue of $6.24 million during the quarter, compared to the consensus estimate of $5.18 million. Arvinas had a negative return on equity of 30.74% and a negative net margin of 171.74%. As a group, analysts anticipate that Arvinas Inc will post -2.4 earnings per share for the current fiscal year.

A number of analysts recently issued reports on the company. Cantor Fitzgerald reissued a “buy” rating and set a $75.00 target price on shares of Arvinas in a research note on Friday, May 29th. Zacks Investment Research raised Arvinas from a “hold” rating to a “buy” rating and set a $36.00 target price for the company in a research note on Tuesday. BidaskClub raised Arvinas from a “hold” rating to a “buy” rating in a research note on Friday, June 26th. Oppenheimer initiated coverage on Arvinas in a research note on Sunday, May 31st. They set a “hold” rating for the company. Finally, Citigroup raised Arvinas from a “neutral” rating to a “buy” rating and set a $45.00 price target for the company in a research report on Monday, June 1st. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Arvinas presently has a consensus rating of “Buy” and an average target price of $55.18.

Arvinas Profile

Arvinas, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer.

Recommended Story: What is Forex?

Want to see what other hedge funds are holding ARVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arvinas Inc (NASDAQ:ARVN).

Institutional Ownership by Quarter for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.